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ABSTRACT _
The first formal economic evaluation of a lipid-lowering
intervention was conducted almost 20 years ago. The
field exploded in the mid-1980s following the publication
of findings from the Lipid Research Clinics Coronary Pri-
mary Prevention Trial (LRC-CPPT), in which the bile-
acid sequestrant, cholestyramine, was reported to reduce
the incidence of coronary artery disease in adults with sig-
nificant elevations in cholesterol. Almost all of the early
pharmacoeconomic studies that followed focused on this
agent. Later in the decade, the introduction of lovastatin,
the first 3-hydroxy-3-methylglutaryl coenzyme A (HMG-
CoAl reductase inhibitor (or "statin"), revolutionized the
treatment of hypercholesterolemia, as it was significantly
more effective than earlier agents (as were the other
statins that followed it). Pharmacoeconomic studies of the
T his article provides a brief historical back-ground on the economics of hypercholester-
olemia and lipid-lowering therapy, and attempts
to characterize the evolution of this field over the
last 10-15 years in relation to the clinical knowl-
edge base that underpins it. Such a task is somewhat
daunting, since there have been many important
contributions to this field. This review, therefore,
concentrates on those clinical and economic stud-
ies that I believe represent important milestones
(Table 1). This is followed by a brief consideration
of those issues that are likely to be of concern in
the years ahead. For those who have been active
participants in this field and who have contributed
to the literature over the last few years, this will be
familiar territory. But for those relatively new to
the field, I hope that an historical tour may be of
value in understanding some of the issues that
concern us today.
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statins generally have reported that, despite their higher
cost, they are significantly more cost-effective than bile
acid sequestrants. Recent long-term clinical trials, such
as the West of Scotland Coronary Prevention Study
(WOSCOPS) and the Scandinavian Simvastatin Survival
Study (45), have provided firm evidence of the benefits of
the statins in both the primary and secondary prevention
of coronary artery disease. Formal economic evaluations
were incorporated into most of these end-point studies-
in contrast to morbidity and mortality trials of earlier
lipid-lowering agents-and results from these evaluations
are just now becoming available. The availability of pri-
mary economic data derived directly from large-scale,
long-term clinical trials raises important questions about
the future role of modeling in this area.
The Pioneers
Twenty years ago, there was considerable evi-
dence suggesting that cholesterol played a key role
in the development of coronary artery disease.
Pathologic and morphologic data, for example,
showed the presence of cholesterol in atheroscle-
rotic plaques, and various studies demonstrated
the induction of atherosclerotic lesions in animals
that were fed high-cholesterol diets. In addition,
single-population and cross-cultural studies re-
ported that cholesterol was a strong predictor of
cardiovascular morbidity and mortality. Finally, a
clear association had been established between a
genetic predisposition to high cholesterol and fam-
ily tendencies to early coronary artery disease. At
the same time, however, definitive clinical evi-
dence of the benefits of drug therapy to lower cho-
lesterol levels was lacking.
The oldest economic evaluation of a lipid-low-
ering intervention was carried out by Berwick,
Cretin, and Keeler, in a pioneering study of chil-
dren [1]. Berwick and colleagues considered the
cost-effectiveness of various intervention strategies
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Table I Important economic evaluations of lipid-lowering interventions
Author
Berwick et al., 1981 [I]
Oster & Epstein. 1986 [3]
Oster & Epstein. 1987 [8]
Martens et al., 1989 [IOJ
Goldman et al., 1991 [IIJ
Pederson et al., 1996 [16]
Oster et al., 1996 [I 7J
Focus
Cost-effectiveness of dietary
intervention in children
Economic benefits of cholesterol-
lowering in adult men
Cost-effectiveness of cholestyramine
in primary prevention
Cost-effectiveness of simvastatin in
primary prevention
Cost-effectiveness of lovastatin in
secondary prevention
Cost-effectiveness of simvastatin in
secondary prevention
Effectiveness and costs of lovastatin
vs stepped care
Significance
First cost-effectiveness analysis of lipid-
lowering strategies
First analysis of direct and indirect
economic benefits of lowering
cholesterol
First cost-effectiveness analysis of drug
therapy
First cost-effectiveness analysis of statins
First cost-effectiveness analysis of drug
therapy in secondary prevention
First trial-based ("piggyback") evaluation of
economic effects of drug therapy
First effectiveness trial of drug therapy
in 10-year-old children. They posited that inter-
ventions in children would produce a sustained re-
duction in the lifetime risk of coronary heart
disease (CHD). Berwick et a1. considered widely dif-
ferent strategies for achieving lower levels of cho-
lesterol, including 1) universal screening and di-
etary modification, 2) targeted screening based on
a family history of CHD coupled with dietary
modification, and 3) a mass-media program to re-
duce levels of dietary fat on a population-wide ba-
sis. Their study was the first to model the benefits
of cholesterol-lowering therapy using logistic risk
functions from the Framingham Heart Study.
Berwick and colleagues considered the costs of
screening and dietary counseling for both the uni-
versal and targeted screening strategies, as well as
the cost of the mass-media campaign. They did
not take into account, however, the economic ben-
efits associated with the avoidance of coronary
events in persons with reduced levels of choles-
terol, probably because at the time the methods to
assess the magnitude of these costs were still in
their infancy. They compared the different strate-
gies in terms of their costs per life-year saved.
Costs and benefits were both discounted at an an-
nual rate of 5% in their analysis. Although the
discounting of benefits in health-economic evalua-
tions has remained somewhat controversial, Ber-
wick and colleagues present an eloquent argument
why benefits must be discounted along with costs,
and at the same rate.
Berwick et a!' reported that a population-wide
intervention based on a mass-media program was
the most cost-effective approach, with a cost per
life-year saved of $3200 ($US, 1975). This was
compared to costs per life-year saved of $7000
and $10,000 for targeted and universal screening,
respectively. Berwick and colleagues concluded
that the clinical benefits of lipid-lowering therapies
were achievable at a relatively low cost through
dietary change. Through their pioneering use of
Framingham Heart Study logistic functions [2],
those of us who have followed in their footsteps
owe them a tremendous intellectual debt for lead-
ing the way in defining the methodology and
power of these techniques.
Pharmacotherapy in the 19805: The Age
of Cholestyramine
In the early 1980s, the Lipid Research Clinics Cor-
onary Primary Prevention Trial (LRC-CPPT) [3]
provided definitive evidence of the clinical benefits
of lipid-lowering therapy in adults. The LRC-
CPPT involved 3806 men with plasma cholesterol
levels above the 95th percentile despite lipid-low-
ering diets, who were free of other lipid disorders
and had not experienced a coronary event. Partici-
pants were randomly assigned either to choles-
tyramine therapy or placebo. After a mean follow-
up of 7.4 years, patients taking cholestyramine
had an 8.5% decrease in their cholesterol levels,
and a 19% decline in the incidence of major coro-
nary events compared to those in the placebo
group. On the basis of these findings, the National
Institutes for Health (NIH) concluded, "It has
been established beyond reasonable doubt that
lowering cholesterol levels will reduce risk of heart
attacks caused by CHD." The LRC-CPPT, there-
fore, firmly established the primary prevention of
CHD as the goal of lipid-lowering therapy in
adults. For those of us in the field of pharrnacoeco-
nomics, this trial had a second major consequence:
It opened the floodgates to economic evaluations of
hypercholesterolemia and lipid-lowering therapy.
The Economics ofLipid-Lowering Therapy
The first formal analysis of the economic bene-
fits of cholesterol-lowering therapy in adults was
reported in 1986 in a study published in the
American Journal of Public Health [4]. Following
in the steps of Berwick et al. [1], Epstein and I
used risk models based on the Framingham Heart
Study. Our work departed from this earlier study,
however, by linking incidence-based, cost-of-ill-
ness estimates to the risk functions from Framing-
ham. This linkage provided the groundwork for
projecting future costs of CHD in relation to cho-
Iesterol level, and accordingly, cost savings associ-
ated with cholesterol-lowering therapy as a conse-
quence of the expected reduction in disease risk.
Our analyses considered the direct and indirect
economic benefits of lowering cholesterol in men
35-74 years of age with preintervention choles-
terollevels of 260,300, and 340 mg/dL. We exam-
ined the benefits of therapy in patients who had no
other risk factors other than hypercholesterolemia,
those who also smoked, and those who also
smoked and were hypertensive and diabetic. Our
study was the first to examine the relation between
the economic benefits of cholesterol-lowering and
patient coronary risk profile (i.e., age, baseline
cholesterol level, and other coronary risk factors).
We assumed that cholesterol-lowering therapy
would confer no benefits for the first 2 years, an
assumption based on results from the LRC-CPPT.
Thereafter, it was assumed that patients would re-
alize 80% of the difference in naturally occurring
levels of risk between post- and preintervention
levels of cholesterol. In other words, if there was a
difference of 20% in the risk of CHD in individu-
als receiving cholesterol-lowering therapy, we as-
sumed that only 80% of that 20%, or 16%, would
be the overall benefit. Also included in the calcula-
tion of benefits was the cost of higher noncardiac
treatment due to living longer; these costs were de-
ducted from our estimates of direct economic bene-
fits. This is an issue that has been debated exten-
sively in the field of health economics for a number
of years-namely, how to handle the cost of living
longer [5,6].
Our findings suggested that the direct cost sav-
ings (discounted net present value) per patient of
lipid-lowering therapy ranged from $3 to $208
($US, 1980); corresponding values for indirect
cost savings ranged from $1 to $9000 (3% dis-
count rate). Direct benefits were greatest for mid-
dle-aged men, 50-54 years of age, parallel with
the greatest absolute reduction in risk, and the
benefits were roughly two-fold higher for high-
risk compared to low-risk patients.
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In the years following the publication of the
LRC-CPPT findings, a number of studies of the
cost-effectiveness of cholestyramine were also re-
ported in the literature. The first was in an edito-
rial by Himmelstein and Wohlhandler published
in the New England Journal of Medicine [7], in
which it was reported that the cost per life-year
saved with cholestyramine was about $1 million.
Subsequently, Weinstein and Stason also reported
informal estimates of the cost-effectivenessof choles-
tyramine therapy in the Annual Reoieto of Public
Health [8].
The first formal analysis of the cost-effective-
ness of cholestyramine therapy was reported in
1987 in the Journal of the American Medical As-
sociation [9]. Epstein and I examined the cost-
effectiveness of cholesryrarnine therapy in men 35-
74 years of age at initiation of therapy with pre in-
tervention total cholesterol levels of 265, 290, and
315 mg/dL alternatively. We considered patients
with three different coronary risk profiles: 1) no
other risk factors except high cholesterol; 2) a sin-
gle additional risk factor (smoking); and 3) three
additional risk factors (smoking, hypertension,
and diabetes). Following from our earlier work on
the economic benefits of cholesterol-lowering, we
used incidence-based cost-of-illness methods cou-
pled with risk models based on Framingham data.
We considered the impact of therapy on the inci-
dence of both fatal and nonfatal events; our model
incorporated higher rates of mortality for patients
who experienced the latter. We assumed that
cholestyramine therapy (16 gld, the mean dosage
in the LRC-CPPT) conferred no benefits for the
first 2 years, but 100% of the difference in natu-
rally occurring levels of risk thereafter. The costs
of living longer, in terms of higher noncardiac
treatment costs, were deducted from the savings
derived from coronary events averted.
We reported that the increase in life expectancy
with cholesryramine ranged from approximately 1
week for men 65-69 years of age at initiation of
therapy, to 0.6 years for those 35-39 years of age
when they began treatment. These results were
similar to those reported by Taylor and colleagues
in the Annals of Internal Medicine [10]. We calcu-
lated that the cost-effectiveness of cholestyramine
ranged from $50,000 to $1 million per life-year
saved ($US, 1985), discounted at a 5% annual
rate. Therapy was reported to be cost-effective in
younger patients with additional coronary risk
factors as well as with severe elevations in choles-
terol. Conversely, treatment was reported not to
be cost-effective in those with only modest eleva-
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tions in cholesterol, especially in men older than
65 years of age.
Pharmacotherapy in the 1990s: Here Come
the Statins
A few years after the publication of the LRC-CPPT
findings, lovastatin, the first 3-hydroxy-3-methyl-
glutaryl coenzyme A (HMG-CoA) reductase inhibi-
tor (or "statin"), was introduced in the United
States. This was followed shortly thereafter by two
additional agents of the same class, simvastatin and
pravasratin, In controlled clinical trials, lovastatin (as
well as the other statins that followed it) was re-
ported to be highly effective and well tolerated.
There was no evidence, however, of a mortality ben-
efit associated with lovastatin therapy, and there
were concerns about its long-term safety (e.g., oph-
thalmic exams were recommended in package label-
ing when the product was introduced). Becauseof its
higher price, significant concerns also were expressed
about the cost-effectiveness of lovastatin therapy.
In 1988, the Expert Panel of the National Cho-
lesterol Education Program released its first re-
port. It recommended drug therapy for patients
who had low density lipoprotein (LDL) choles-
terol levels above 160 mg/dL and two or more
coronary risk factors or known CHD. The panel
also recommended therapy for individuals who
had fewer than two additional risk factors but
LDL cholesterol levels in excess of 190 mg/dL.
The panel designated niacin and the bile acid se-
questrants as the drugs of first choice and recom-
mended lovastatin, the only statin available at the
time, for patients not successfully treated with the
other agents.
The first comprehensive pharmacoeconomic eval-
uation of an HMG-CoA reductase inhibitor (simva-
statin) in primary prevention of CHD was re-
ported by Martens and colleagues in the American
Journal of Medicine in 1989 [11]. In contrast to
the studies that preceded it, they considered the
cost-effectiveness of therapy in women as well as
in men. Patients were assumed to have pretreat-
ment cholesterol levels of 290, 310, and 330 mg/
dL. The analysis was based on risk models devel-
oped using data from the Framingham study; the
costs of CHD were based on estimates derived
from a Delphi panel. The costs of living longer
were not considered in the analysis.
Martens reported that the cost per life-year
saved was four- to five-fold lower for simvastatin
than for cholestyramine. Cost-effectiveness ratios
were $25,000 to $55,000 for the former versus
Oster
$110,000 to $265,000 for the latter ($US, 1985).
Cost-effectiveness ratios were significantly higher
for women than for men. Based on these results,
Martens et aI. concluded that simvastatin was the
agent of first choice for the treatment of hypercho-
lesterolemia. Subsequent studies by other research-
ers have confirmed the cost-effectiveness of simva-
statin and other HMG-CoA reductase inhibitors
in primary prevention.
The first cost-effectiveness analysis of a statin
(lovasratin) in secondary prevention-that is, in per-
sons with symptomatic CHD-was reported by
Goldman et at. in the Journal of the American Med-
ical Association in 1991 [12]. Their study was based
on a multimodule, state-transition model termed the
"Coronary Heart Disease Policy Model," which
was developed by researchers at the Harvard School
of Public Health [13].
Goldman and colleagues reported that the cost-
effectiveness of secondary prevention varied sig-
nificantly according to patients' age and pretreat-
ment cholesterol level. For young men with exist-
ing CHD and total cholesterol levels greater than
250 mg/dL, lovastatin therapy was reported to
save lives and reduce overall costs of care-a win-
win outcome. For all others with total cholesterol
levels greater than 250 mg/dL, lovastatin therapy
was not cost-saving but was reported to be of ac-
ceptable cost-effectiveness; ratios were consistently
less than $20,000 per life-year saved ($US, 1989).
For persons with cholesterol levels below 250 mg/
dL, cost-effectiveness ratios for lovastatin therapy
were reported to range from approximately $16,000
to $38,000 for men, and from $23,000 to $210,000
for women.
Goldman et al. also used their model to assess
the cost-effectiveness of lovastatin in primary pre-
vention. For those with total cholesterol levels of
300 mg/dL, cost-effectiveness ratios were reported
to range from $15,000 to $330,000 per life-year
saved for men, and from $34,000 to $1.5 million
for women. Therapy was found to be most cost-
effective in nonelderly persons with multiple risk
factors, in keeping with the pattern of results re-
ported by other authors. For individuals with total
cholesterol levels between 250 and 300 mg/dL,
cost-effectiveness ratios ranged from $27,000 to
$690,000 per life-year saved for men; for women,
ratios were always in excess of $50,000.
This study was important because it was the
first to consider the cost-effectiveness of secondary
prevention with lipid-lowering drugs. Their find-
ing that secondary prevention was substantially
more cost-effective than primary prevention led
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the authors to conclude that the recommendations
regarding cholesterol reduction were not suffi-
ciently aggressive with respect to persons with pre-
existing CHD. In keeping with the findings of
earlier studies, they also concluded that therapy
for primary prevention should be based on risk
profiles.
In the last several years, a number of large trials
have been undertaken to examine the impact of
treatment with statins on CHD morbidity and
mortality in primary as well as in secondary pre-
vention. The most notable among these trials in-
clude: 1) the Scandinavian Simvastatin Survival
Study (4S) [14], which examined secondary pre-
vention in patients with total cholesterol levels
above 260 mg/dL; 2) the West of Scotland Coro-
nary Prevention Study (WOSCOPS) [15), which
examined the benefits of pravastatin therapy in
persons free of CHD with total cholesterol levels
in excess of 270 mg/dL; and 3) the Cholesterol
and Recurrent Events (CARE) study [16], which,
like 4S, was a secondary prevention study, but in-
volved participants with cholesterol levels less than
228 mg/dL who were treated with pravastatin.
Taken as a whole, these trials have provided per-
suasive evidence of the benefits of statins in both
primary and secondary prevention.
From a pharmacoeconomic perspective, these
trials are important also because so-called "piggy-
back" economic evaluations were undertaken in
conjunction with them. One of the first such anal-
yses, which was based on 4S, was reported by
Pederson et al. in Circulation [17]. In 45, simva-
statin therapy was reported to reduce the risk of
death by 30% over 5.4 years in patients with pre-
vious myocardial infarction (MI) or stable angina.
Pederson et al. reported that because the patients
taking simvastatin had fewer clinical events than
those receiving placebo, they spent less time in a
hospital, resulting in an estimated savings of $3900
per patient over the course of the trial, Based on
these savings, the authors calculated that the effec-
tive cost of simvastatin therapy in this patient pop-
ulation was reduced by almost 90% to only about
28 cents per day. Additional studies on the cost-
effectiveness of pravastatin therapy in primary and
secondary prevention, based on WOSCOPS and
CARE, respectively, are forthcoming.
Efficacy versus Effectiveness: The Cholesterol
Reduction Intervention Study
One question that has dogged the field of pharma-
coeconomics for a number of years is the extent to
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which results from highly structured clinical trials
that examine questions of efficacy can guide us in
understanding the outcomes of drug therapy un-
der conditions of typical clinical practice. The
Cholesterol Reduction Intervention Study (CRIS)
[18] was undertaken to address this question. It
was one of the first clinical trials of a drug therapy
to utilize a so-called "pragmatic" design (19).
CRIS was undertaken at Southern California
Kaiser Perrnanente, a large managed-care organi-
zation. More than 600 patients who were candi-
dates for drug therapy were randomized either to a
stepped-care regimen, starting with niacin and then
progressing to bile acid sequestrants and ending
with lovastatin, or to initial treatment with lova-
statin, Throughout the study patients remained un-
der the care of their usual providers, all of whom
were instructed to treat patients to goal choles-
terol level. To approximate conditions of typical
clinical practice, provider compliance with the
treatment plan to which patients were randomized
was encouraged but not enforced. Unlike most other
clinical trials, subjects in CRIS paid for their medi-
cation as they would typically; patients may be
less compliant, for example, with medication regi-
mens that involve higher out-of-pocket costs. De-
spite the fact that many of us have formal training
as economists, this is an issue that we have too
long ignored.
The traditional efficacy paradigm suggested
that outcomes (i.e., percentage of patients attain-
ing goal cholesterol level) should have been the
same in both of the treatment groups: stepped-
care patients who did not attain goal with niacin
and/or a bile acid sequestrant ultimately should
have been prescribed other agents including lova-
statin, which was the final agent in this cascade.
The findings from CRIS, however, raise important
questions about our ability to generalize from tra-
ditional (i.e., efficacy) clinical trials to clinical
practice. The trial found that patients randomized
to stepped care were significantly less likely to at-
tain goal cholesterol level and less likely to be still
taking their cholesterol-lowering medication at 1
year-no doubt, because of the higher incidence
of side-effects that they experienced (Table 2). Es-
timated costs of care among lovastatin patients
were about $1 more per day.
Where to Go from Here
As a formal field of investigation, the economics
of hypercholesterolemia and lipid-lowering ther-
apy is almost 20 years old. The questions that we
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Table 2 Results of the Cholesterol Reduction Intervention Study (CRIS)*
Oster
Outcome!
Attained goal LDLcholesterol
Experienced bother due to side effects
Discontinued medication
Lovastatin (%)
40
16
18
Stepped care (%)1
24
30
28
p
<0.001
<0.001
<0.001
"Dara from [17].
tAt I year.
'In stepped care. patients were treated initiallywith niacin, followed by other agents if needed.
have addressed have evolved over time, beginning
with the value of dietary change in children and
evolving as our clinical knowledge base has grown.
There are new questions that I believe we now need
to consider.
The first concerns our track record-that is, the
accuracy of our crystal ball. Model-based cost-
effectiveness studies of the statins were first pub-
lished in the late 1980s, years before data were
available from end-point trials. How do our mod-
els fare in light of results from studies such as
WOSCOPS or 4S? How accurate have our policy
recommendations been? This seems to me to be a
particularly important question, as it relates to our
ability to inform clinical decision-making under
conditions of imperfect knowledge and uncertainty.
It also is important in light of on-going discussions
in the United States about the role of prediction ver-
sus observation in pharmacoeconomic assessments.
On the surface, I think the predictions of our mod-
els accord reasonably well with the results of re-
cent clinical investigations. This question is deserv-
ing, however, of a more than cursory examination,
and I hope that the current generation of research-
ers examines this issue closely.
A second and related question concerns the role
of modeling with respect to lipid-lowering agents
for which results from large end-point trials are
not yet available, and perhaps never will be (e.g.,
fluvastatin, atorvastatin, cerevastatin), Is it appro-
priate to assume that demonstrated benefits for
some HMG-CoA reductase inhibitors can be gen-
eralized to all of the agents in this class? On the
one hand, were it not for our willingness to live
with the uncertainty attendant with modeling, we
would not have been able to say anything, for ex-
ample, about the cost-effectiveness of the statins
relative to earlier agents until the former had been
on the market for a number of years. On the other
hand, I think we need to exercise a bit more cau-
tion in the assumptions that we employ in our
models, as seemingly unimportant differences in
pharmacology may yield significant differences in
clinical outcomes. One prudent solution might be
to limit cost-effectiveness evaluations for agents
without morbidity or mortality data to the use of
intermediate end-points and proximal measures of
cost-effectiveness (e.g., cost per 1% reduction in
LDL cholesterol) rather than cost per life-year
saved. Relevant healthcare personnel could then
make their own decisions about generalizing clini-
cal effects established for other drugs to the one in
question.
Our knowledge of the clinical and economic
benefits of cholesterol-lowering therapies has in-
creased significantly over the last 20 years. As we
answer some questions, others arise. Hopefully,
the reactor panel that follows will assist us in ad-
dressing some of these new issues.
This article was prepared with the assistanceof BioMed-
Com Consultants inc., Montreal, Canada.
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